Overall survival, MDS subtypes

• There is little information on which MDS subtypes might benefit more from ICT.
• In one analysis, patients with lower IPSS risk MDS receiving ICT had significantly superior OS in the subtypes RA and RARS/RARS-t, but not in RCMD/RCMD-RS, RAEB1, MDSU&MDS/ MPNU, or del(5q)MDS, though this study was limited by small sample sizes in the latter groups.
• Although there was no difference in OS between ICT & non-ICT patients with RCMD/ RCMD-RS, clear HI-E occurred in 3 ICT patients in this group with a >50% reduction in RBC transfusion requirements in 2 patients & long term transfusion independence resulting in significantly improved QOL in a 3^rd.